Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme by Tejeda, Gonzalo S. et al.
Chorea-related mutations in PDE10A result in aberrant
compartmentalization and functionality of the enzyme
Gonzalo S. Tejedaa, Ellanor L. Whiteleya,1, Tarek Z. Deebb, Roland W. Bürlic, Stephen J. Mossb,d, Eamonn Sheridane,
Nicholas J. Brandonf,2,3, and George S. Bailliea,3
aInstitute of Cardiovascular and Medical Science, University of Glasgow, G12 8QQ Glasgow, United Kingdom; bAstraZeneca-Tufts University Laboratory for
Basic and Translational Neuroscience Research, Tufts University School of Medicine, Boston, MA 02111; cNeuroscience, IMED Biotech Unit, AstraZeneca,
CB21 6GH Cambridge, United Kingdom; dDepartment of Neuroscience, Tufts University School of Medicine, Boston, MA 02111; eInstitute of Biomedical and
Clinical Sciences, University of Leeds, LS9 7TF Leeds, United Kingdom; and fNeuroscience, IMED Biotech Unit, AstraZeneca, Boston, MA 024515
Edited by Joseph A. Beavo, University of Washington School of Medicine, Seattle, WA, and approved November 20, 2019 (received for review October
15, 2019)
A robust body of evidence supports the concept that phosphodi-
esterase 10A (PDE10A) activity in the basal ganglia orchestrates
the control of coordinated movement in human subjects. Although
human mutations in the PDE10A gene manifest in hyperkinetic
movement disorders that phenocopy many features of early
Huntington’s disease, characterization of the maladapted molecular
mechanisms and aberrant signaling processes that underpin these
conditions remains scarce. Recessive mutations in the GAF-A do-
main have been shown to impair PDE10A function due to the loss
of striatal PDE10A protein levels, but here we show that this pau-
city is caused by irregular intracellular trafficking and increased
PDE10A degradation in the cytosolic compartment. In contrast to
GAF-Amutants, dominant mutations in the GAF-B domain of PDE10A
induce PDE10A misfolding, a common pathological phenotype in
many neurodegenerative diseases. These data demonstrate that
the function of striatal PDE10A is compromised in disorders where
disease-associated mutations trigger a reduction in the fidelity of
PDE compartmentalization.
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Cyclic nucleotide signaling plays a critical role in the regula-tion of coordinated movement in the basal ganglia. The
duration, amplitude, and subcellular localization of cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate
(cGMP) signals are tightly regulated by phosphodiesterases (PDEs).
PDE10A coordinates cAMP signaling in striatal medium spiny
neurons, the main input region of the basal ganglia circuitry and the
most vulnerable cells to degeneration during Huntington’s disease
(HD) (1, 2). This distribution pattern positions PDE10A as an ef-
fector in motor control and as an attractive therapeutic target for
basal ganglia diseases. Furthermore, PDE10A protein levels are
reduced in HD and Parkinson’s disease (3–5), with the decline
preceding the onset of motor symptoms and progressing over the
course of the disease (6–12). The role of PDE10A in the reg-
ulation of coordinated movement has been further established
by both dominant and recessive mutations in this gene as causes of
childhood-onset hyperkinetic syndromes (13–16). Patients with
dominant heterozygous mutations in PDE10A (F300L, F334L, and
F334C) displayed symmetrical striatal bilateral lesions, as shown by
MRI (14–17). These substitutions located in the regulatory GAF-B
domain do not alter the basal activity of PDE10A but they inhibit
the cAMP-stimulatory effect for cGMP hydrolysis, as reported for
F300L and F334L mutations (15). Moreover, subjects carrying the
F300L modification showed a significant decrease in striatal
PDE10A levels (17). In contrast, familial homozygous mutations in
PDE10A have been detected in a conserved region of the GAF-A
domain (Y107C and A116P) and MRI imaging of affected indi-
viduals did not show alterations in overall brain structure (13). The
motor abnormalities produced by the GAF-A mutations are the
result of reduced PDE10A activity in the striatum due to a loss in
protein levels.
It is expected that the disease phenotypes are due to the ab-
errant function of the major striatal splice variant PDE10A2.
This isoform is located in the plasma membrane associated with
other synaptic proteins (18). Translocation and anchoring of
PDE10A2 to the membrane is achieved by irreversible palmi-
toylation at C11 of the newly synthesized enzyme, although this
posttranslational modification can be prevented by phosphory-
lation at T16 by protein kinase A (PKA) (19). The 2 other
prevalent isoforms in humans, PDE10A1 and PDE10A19, have a
cytosolic localization due to the lack of the N-terminal cysteine
residue (20, 21). In transgenic HD models, the loss of striatal
PDE10A2 is thought to be the consequence of transcriptional
repression by mutant huntingtin (mHTT) (3). However, protein
degradation could also play a role in the down-regulation of
PDE10A in these diseases. Protein stability of this enzyme seems
to be regulated by the ubiquitin proteasome system (UPS), as
the increased expression of proteasomal components reduces
PDE10A levels in striatal neurons of an HD mouse model (22).
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Additionally, activation of lysosomal function by overexpression
of the transcription factor EB decreases PDE10A levels in the
same HD model (23), suggesting an alternative route of degra-
dation that could be isoform-specific or dependent on differen-
tial subcellular localization (24). This complexity hinders the
search for the effectors involved in PDE10A dysregulation, while
the pathological mutations in this gene offer an opportunity for a
straightforward identification of these mechanisms. In this work
we compare the basic cellular biology and proteostasis of the
GAF-A and GAF-B PDE10A mutants and propose molecular
mechanisms responsible for reduced PDE10A levels in affected
individuals.
Results
Pathological Mutations in the GAF-A Domain of PDE10A Impair Its
Enzymatic Activity at the Plasma Membrane. Disease phenotypes
caused by PDE10A GAF-A and GAF-B mutations have been
linked to aberrant PDE activity. Thus, in vitro PDE assays have
shown a diminished capacity to degrade cAMP in striatal lysates
from a knockin mouse carrying the mutated PDE10A GAF-A
variant homologous to the human Y107C (13). Furthermore,
experiments in membrane fractions of COS7 cells with the
F300L and F334L PDE10A variants exhibited a normal enzy-
matic basal activity but an impaired cAMP-stimulatory effect for
cGMP hydrolysis (15). Considering that both PDE10A Y107C
and F300L mutants share pathological features, we first wanted
to compare their enzymatic activities. As phenotypes under-
pinned by PDE10A mutations are caused by functional abnor-
mality of the most abundant isoform, we generated plasmids
containing PDE10A2-FLAG with the human GAF-A mutations
Y107C and A116P and the GAF-B mutations F300L and F334L.
Membrane fractions from HEK293 cells transiently transfected
with these constructs or the PDE10A2 WT were used for in vitro
assays to measure PDE activity (Fig. 1A). The ability to hydro-
lyze cAMP with increasing concentrations of the highly selective
PDE10A inhibitor MP10 was similar between PDE10A2 WT,
F300L, and F334L forms, confirming previous reports (15). In
contrast, PDE activity of the Y107C or the A116P mutants was
not measurable in the membrane fraction, consistent with the
results from the knockin mouse (13). However, these assays may
not reflect the cAMP dynamics in the membrane of a living cell.
In light of this, we performed electrophysiological experiments
to monitor changes in intracellular cAMP levels due to the activity
of these PDE10A mutants. We overexpressed cyclic nucleotide-
gated (CNG) channels in HEK293 cells as a cAMP biosensor (25,
26), ADCY3 to stimulate endogenous cAMP production, one of
the PDE10A2 variants, and GFP. Cultures were preincubated with
rolipram until a stable baseline was achieved, in order to eliminate
endogenous PDE4 activity that can prevent CNG channel activa-
tion (27). Then, cells were treated with forskolin and PDE10A
activity was assessed by measuring the increase in current after
subsequent addition of MP10 (Fig. 1B). Cells expressing PDE10A2
WT and GAF-B mutant forms exhibited an increase in the CNG-
mediated currents after MP10 treatment (Fig. 1C). In stark con-
trast, MP10 application did not further activate CNG currents in
cells expressing the Y107C or A116P variants. Do the mutations in
the GAF-A domain abolish the capacity of PDE10A2 to hydrolyze
cAMP?Or do they affect its trafficking to the plasma membrane as
depending on palmitoylation levels (19)? To explore these possi-
bilities, we compared cAMP fluctuations in the cytosol and the
plasma membrane using a FRET reporter. Cytosolic or membrane
cAMP FRET sensors alongside the different PDE10A2 variants or
the cytosolic isoform PDE10A1 were coexpressed in HEK293 cells
(SI Appendix, Fig. S1A) (28). Cultures were treated with forskolin,
followed by MP10 to assess PDE10A activity. As expected, cells
with PDE10A1 exhibited a dramatic increase in FRET response in
the cytosol after treatment with MP10, which was absent from the
membrane (Fig. 1D). In contrast, overexpression of PDE10A2
F300L caused a higher cAMP change in the plasma membrane,
resembling the response obtained with the WT. Interestingly, cells
expressing the PDE10A2 GAF-A mutants displayed a marked
FRET change in the cytosol. This suggests that the pathological
mutations in the GAF-A domain of PDE10A2 do not hinder en-
zymatic activity per se, but reduce the translocation of the protein
to the plasma membrane.
Mutations in GAF-A and GAF-B Domains of PDE10A Differentially Alter
the Subcellular Localization of PDE10A Protein. The depleted activity
of PDE10A2 Y107C and A116P observed at the plasma mem-
brane compelled us to evaluate the expression and localization of
the GAF-A and GAF-B mutants. Initially, we compared the
transfected GAF-A and GAF-B mutations levels to WT forms.
Analysis of mRNA levels showed no difference in expression
among all PDE10A variants (SI Appendix, Fig. S1B), but im-
munoblots detecting the recombinant proteins (Fig. 2A) con-
firmed significantly lower levels of Y107C and A116P mutants in
comparison to PDE10A2 WT (Fig. 2B), similar to PDE10A1.
Next, we studied cellular distribution. Crude fractionation con-
firmed that PDE10A1 WT was primarily in the cytosol, whereas
PDE10A2 WT was mainly located in the plasma membrane (Fig.
2C). However, a fraction of PDE10A2 could also be detected in
the cytosol (Fig. 2D), which might be attributed to the PKA-
phosphorylated pool (19). Interestingly, both PDE10A2 Y107C
and A116P were observed at significantly greater levels in the
cytosolic fraction than the WT form. The PDE10A2 GAF-B
mutants also showed a substantial reduction in the membrane-
to-cytosol ratio, although proportion in the membrane was
higher than in the GAF-A mutants. Validation of the cytosolic
and membrane fractions was confirmed by probing for GAPDH
and E-cadherin, respectively (Fig. 2C).
To extend these findings, we performed immunofluorescence
studies to visualize the distribution of PDE10A forms in trans-
fected HEK293 (Fig. 2E), SH-SY5Y (SI Appendix, Fig. S1C),
and PC12 cells (SI Appendix, Fig. S1D). Confocal images cor-
roborated the cytosolic localization of PDE10A1 and the pre-
dominantly membrane staining of PDE10A2 WT. Consistent
with the fractionation studies, mutations in the GAF-A domain
of PDE10A2 abolished plasma membrane localization and
showed a cytosolic distribution (Fig. 2F). Interestingly, both
PDE10A2 GAF-B mutants extensively accumulated in aggre-
gates within the cytoplasm and the perinuclear region in ∼75%
of transfected cells (Fig. 2G). However, a reduced proportion of
these forms could still be observed at the plasma membrane.
Smaller aggregates were also detected in cells with PDE10A2
WT, probably due to overexpression, but significantly lower than
that observed for F300L and F334L mutants. These results
suggest that GAF-A and GAF-B mutants alter PDE10A distri-
bution in different ways, likely dysregulating cyclic nucleotide
levels within different compartments, which might be important
to explain the differences in clinical presentation. Furthermore,
changes in cAMP levels induced by inhibition of endogenous
PDE4 do not seem to affect the distribution of the different
PDE10A2 variants (SI Appendix, Fig. S1E).
Mechanism of PDE10A Degradation Depends on Its Subcellular
Localization. It has been suggested that proteostasis depends on
subcellular localization, with cytosolic proteins being subjected to
UPS degradation, while membrane proteins usually undergo
proteolysis through the autophagy-lysosomal pathway (ALP) (29).
Consequently, we investigated if the subcellular mislocalization of
PDE10A mutants changed the route of PDE10A proteostasis. To
test this hypothesis, transfected cells were treated with MG132
for various periods of time (Fig. 3A). PDE10A1 significantly
accumulated after proteasome inhibition while the membrane-
anchored PDE10A2 WT levels did not. Similarly, protein levels
of both GAF-B mutations remained stable throughout the time
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course. A different result was obtained for the GAF-A mutants
where significantly elevated protein levels were observed after
MG132 treatment. These results indicate that the subcellular lo-
calization of PDE10A is critical for the action of the UPS. How-
ever, this apparent increased degradation of PDE10A2 Y107C
and A116P could also be a consequence of aberrant ubiquitina-
tion. Therefore, we decided to immunoprecipitate ubiquitinated
proteins following proteasomal inhibition (Fig. 3B). Immuno-
blotting for the FLAG tag showed that both PDE10A2 WT and
the GAF-A mutant forms can be ubiquitinated. Moreover,
MG132 treatment significantly increased the levels of the coim-
munoprecipitated Y107C and A116P variants (Fig. 3C), indicating
that GAF-A forms are more susceptible to ubiquitin-mediated
protein degradation. Next, we wanted to evaluate if the GAF-A
mutations impair the recognition and palmitoylation of the en-
zyme. We purified palmitoylated proteins using resin-assisted
capture of acylated proteins from cells expressing PDE10A1 or
the different forms of PDE10A2. The highly palmitoylated protein
flotillin-2 (30) was used to validate isolation of the palmitoylated
fraction. PDE10A1 did not exhibit any palmitoylation, in contrast
to the robustly palmitoylated PDE10A2 WT (Fig. 3D), as pre-
viously described (19). Accordingly, Y107C and A116P mutations
significantly abolished the palmitoylation of PDE10A2 (Fig. 3E).
Conversely, mutations in the GAF-B domain did not affect
palmitatoylation of PDE10A2 in a significant manner (SI Ap-
pendix, Fig. S2 A and B). Collectively, these results indicate that
chorea-related mutations in the GAF-A domain of PDE10A2
impair its palmitoylation and trafficking to the plasma mem-
brane. This causes accumulation in the cytosol, which increases
its likelihood of being targeted by the UPS. This concept could
help explain the reduction in striatal PDE10A observed in affected
individuals (13).
The resistance of PDE10A2 WT, F300L, and F334L forms to
UPS degradation suggests an alternative route, possibly by the
ALP. In fact, both membrane proteins and insoluble aggregates
are normally eliminated through autophagy (29, 31), a process
that can be controlled by ubiquitination (32). Consequently, we
studied the effect of inhibiting lysosomal degradation on
PDE10A2 forms present in the soluble (SI Appendix, Fig. S2C)
and insoluble fractions (Fig. 4A). Under these conditions, the
levels of all recombinant PDE10A2 variants tested remained
unchanged in the soluble fraction (SI Appendix, Fig. S2D), but a
significant increase of PDE10A2 WT, F300L, and F334L forms
was evident in the insoluble fraction (Fig. 4B). ALP inhibition
was confirmed by the accumulation of the autophagosome
marker p62 (33), which was enriched in the insoluble fraction.
The small proportion of the cytosolic forms in the triton-
insoluble fraction could be explained by their interaction with
components of the detergent-insoluble cytoskeleton, as it has
been shown that PDE10A can bind to cytoskeleton-interacting
AKAP150 in striatal neurons (18, 34). In order to confirm that
the aggregates of PDE10A2 GAF-B mutants are ultimately
cleared by the autophagic system, we examined their colocali-
zation with the endosomal marker EEA1 (Fig. 4C), which has a
role in the fusion with autophagosomes (35), and the lysosomal
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Fig. 1. Chorea-related mutations in GAF-A but not GAF-B domains of
PDE10A alter enzymatic activity. (A) Dose-dependent inhibition of PDE10A
activity in membrane fractions of HEK293 cells transfected with the different
forms of PDE10A2 as shown, over a range of 0.3 μM to 3 mMMP10 and using
2 μM cAMP as substrate. Inhibition profiles represent the mean ± SEM of the
percentage of PDE activity relative to a control without MP10 treatment. (B)
Representative traces of evoked CNG-mediated currents recorded from
HEK293 cells expressing the different PDE10A forms. The time of application
of 5 μM forskolin, 300 nM MP10, and 10 mM MgCl2 is indicated. (C) Quan-
tification of the percentage increase of CNG-mediated potentiation by MP-
10 treatment, relative to the forskolin response. Data are represented as the
mean ± SEM and results analyzed by one-way ANOVA test followed by
Dunnett’s post hoc (***P = 0.0008; n = 5). (D) Quantification of the FRET change
in the cytosolic and membrane compartments in HEK293 cells transfected
with PDE10A1 or the different forms of PDE10A2. Results are represented as
mean ± SEM of the FRET response obtained with 300 nM MP-10 treatment
after subtracting the endogenous signal recorded with a previous applica-
tion of 5 μM forskolin and relative to the saturating response (25 μM for-
skolin and 100 μM IBMX). Differences were evaluated by a two-way ANOVA
followed by Bonferroni’s post hoc (*P = 0.0453 for Y107C and 0.0405 for
F300L, ***P < 0.0001; n = 15).
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marker LAMP1 (Fig. 4F). Line-scan intensity profiles across the
perinuclear region in confocal images (Fig. 4D) showed that the
aggregates were contained in EEA1+-endosomes (verified by
quantitative analysis using Pearson’s correlation coefficient
[PCC]), in contrast to the PDE10A2 WT form (Fig. 4E).
Immunostaining also revealed that the inclusions moderately
overlapped with the lysosome marker (Fig. 4 G and H), illus-
trating a connection with the ALP.
Aggregation of the PDE10A2 GAF-B mutants could be
explained by changes in noncovalent forces between the affected
conserved aromatic residues. The conformation of the WT GAF-
B domain is likely stabilized by an edge-to-face interaction be-
tween F300 and F334 (Fig. 4 I, Center). Both mutated forms
(F300L and F334L) lack this positive interaction and therefore
may display increased conformational flexibility in this region of
the β-sheet. Ultimately, this change in mobility could promote
propensity for aggregation of the GAF-B forms carrying these
mutations.
PDE10A2 F300L and F334L Mutants Accumulate in Aggresomes. Mis-
folded proteins such as PDE10A2 GAF-B mutants are resistant
to proteasomal degradation and are processed by autophagy
(31). Such aggregates are cleared into aggresomes, a pathologi-
cal feature common in several neurodegenerative diseases (36).
A hallmark of aggresomes is the enclosure by vimentin cages (37)
and we could observe the redistribution of this intermediate
filament around the PDE10A2 GAF-B mutant aggregates (SI
Appendix, Fig. S2A). Furthermore, a known component of
aggresomes, p62, was recruited into the PDE10A2 F300L and
F334L inclusions (Fig. 5 A and B), increasing their colocalization
3-fold compared to the WT form (Fig. 5C). Considering that p62
often interacts with polyubiquitinated substrates in aggresomes
(37), we also evaluated the ubiquitin levels of PDE10A2 mutant
aggregates by immunofluorescence (Fig. 5D) and detected
ubiquitin enrichment in large inclusions (Fig. 5 E and F). Fur-
thermore, we also confirmed that these structures were not part
of the Golgi or endoplasmic reticulum complexes (SI Appendix,
Fig. S2F). Surprisingly, the modulator of aggresome formation
HDAC6 (38) did not relocate to the GAF-B mutant inclusions
(SI Appendix, Fig. S3A). Similarly, we also explored the possi-
bility that these aggregates were derived from stress granules
(SG) or P-bodies. We found a strong colocalization of TIA-1,
critical for the early stages of SG-assembly, with the F300L and
F334L aggregates (SI Appendix, Fig. S3B). However, treatment
with the stress-inducer sodium arsenite did not increase cos-
taining with TIA-1 and the mutant forms were not recruited into
the newly formed SGs. Additionally, neither the SG marker
G3BP nor the P-body component Dcp1a accumulated into the
mutant PDE10A2 aggregates (SI Appendix, Fig. S3 C and D).
Nevertheless, it has been reported that TIA-1 can integrate into
insoluble inclusions generated by accumulation of mHTT frag-
ments or misfolded tau (39), and many other proteins are also
shared among the stress-response structures (40).
We decided to evaluate whether the sequestration PDE10A
GAF-B mutations affected the PKA substrate target profile,
such as vasodilator-stimulated protein (VASP) and cAMP re-
sponse element-binding protein (CREB) (Fig. 5G) (13, 41).
Phosphorylation of these substrates was significantly decreased
for PDE10A2 WT but not with F300L or F334L forms (Fig. 5 H
and I), showing that these mutations can modify the overall
cAMP signaling dynamics in the cell. As protein inclusions or
their intermediate species have repeatedly been associated with
the cytotoxicity that underlies cell death in many neurodegen-
erative diseases (42, 43), we next evaluated the effect of PDE10A
aggregates on cellular survival using the xCELLigence system.
No significant differences in cell growth were recorded in cells
overexpressing the GAF-B mutants compared to the WT form
(SI Appendix, Fig. S3E). Thus, we investigated the survival
response of these cells under sodium arsenite treatment. Sur-
prisingly, expression of the aggregate-prone F300L and F334L
mutants demonstrated a higher resistance to stress-induced
death than cells transfected with the WT variant or a mock
control (Fig. 5 J and K). This slower death rate could be con-
sequence of a dysfunctional ALP that would prevent an excessive
elevation of autophagy after high doses of sodium arsenite. For
example, inhibition of the autophagic pathway by taurine treat-
ment in HepG2 cells protects against arsenite-induced toxicity
(44, 45).
PDE10A2 Mutants Exhibit Differential Compartmentalization in
Striatal Neurons. To further validate our data from model cell
lines, we also investigated rat primary striatal neuronal cultures
expressing the PDE10A constructs. Consistent with the distri-
bution pattern in cell lines, PDE10A2 Y107C and A116P showed
a cytosolic localization similar to PDE10A1 (Fig. 6A). Further-
more, treatment with palmitoylation inhibitor 2-bromopalmitate
(2-BP), which promotes cytosolic distribution (19), reduced en-
dogenous levels of PDE10A in striatal neurons, a decrease that
can be prevented by proteasomal inhibition (Fig. 6 B and C).
F300L and F334L mutants accumulated in aggregates in contrast
to the strong membrane immunostaining observed for the WT
form. Interestingly, the size of aggregates in striatal neurons was
10 times smaller than in HEK293 cells, with an average diameter
of 1.3 μm, similar to the ones observed in the neuron-like cells
PC12 and SH-SY5Y (SI Appendix, Fig. S4A). Moreover, neu-
ronal cultures presented a more dispersed distribution of the
aggregates throughout the cell. It has been previously described
that the overall structure of the aggresomes varies depending on
the cell system and the phase of formation when they are studied
as they can fuse to each other (46). This cellular discrepancy was
extended to the components that are recruited into the PDE10A
aggregates. Thus, p62 immunostaining did not colocalize with
the labeled aggregates in striatal neurons (Fig. 6 D–F), although
ubiquitinated proteins were still accumulated in these inclusions
(Fig. 6 G–I). Similarly, relocation of the PDE10A2 mutant
aggresomes to EEA1 was slightly reduced compared to HEK293
cells (SI Appendix, Fig. S4B), while association of these struc-
tures with the P-body marker Dcp1a was increased in the neu-
ronal cultures (SI Appendix, Fig. S4 F and G). Nonetheless,
LAMP1 could also be detected in PDE10A2 F300L and F334L
inclusions (SI Appendix, Fig. S4C), suggesting an autophagic
route for these aggresomes in neurons. No colocalization with
HDAC6 or Golgi and endoplasmic reticulum markers was ob-
served (SI Appendix, Fig. S4 D–F).
Discussion
PDE10A has emerged as a central regulator of motor control
(47) following the identification of single mutations in the en-
zyme that lead to hyperkinetic movement disorders (48). Here,
we show that the underlying mechanisms of these disease-
associated mutations in PDE10A are related to abnormal sub-
cellular localization and aberrant degradation of the enzyme,
which ultimately disrupts the precise balance of compartmen-
talized cAMP signaling. The pathological phenotype observed in
patients correlates to the impairment of the most abundant
striatal splice variant, the membrane-bound PDE10A2 (21).
Trafficking to the plasma membrane is achieved by palmitoyla-
tion on the isoform-specific N-terminal region, although PKA
phosphorylation is able to prevent translocation (19) and main-
tain a small pool of cytosolic PDE10A2. We have shown that
substitutions Y107C and A116P located in the GAF-A domain
prevent trafficking to the membrane in cell lines and primary
striatal neurons. While the GAF-B domain is responsible for
cyclic nucleotide binding and dimerization (49), the function of
the GAF-A region in PDE10A remains elusive. Additionally,
GAF domains in other PDEs have also been implicated in
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protein–protein interactions (50). This work shows that GAF-A
mutations abolish palmitoylation of PDE10A. Therefore, it
could be possible that Y107C and A116P mutations are situated
in the binding region for the palmitoyl transferase (zDHHC), as
some zDHHC substrates contain the interacting site distant from
the palmitoylated residues (51). It is also important to note that
these PDE10A2 mutants retain the ability to hydrolyze cAMP in
a similar manner to the cytosolic PDE10A1. Thus, the di-
minished PDE10A activity at the plasma membrane associated
with the motor disorder, reinforces the paradigm of compart-
mentalized cAMP dynamics being crucial for normal cell func-
tion (52). This has been exemplified before with the displacement
of PDE4D7 from the plasma membrane, leading to aberrant
cAMP signaling and an increase in the proliferation of prostate
cancer cells (53). The shift of PDE10A2 GAF-A mutants to
the cytosol also increases the turnover rate compared to the
membrane-bound form. Indeed, they exhibit similar vulnera-
bility to proteasomal degradation as PDE10A1, which agrees
with the predominant action of the UPS pathway on cytosolic
proteins (54). In fact, the elevation of the proteasomal activity
by overexpression of NUB1 has been shown to decrease PDE10A
levels in an HD mouse model (22). In contrast, the PDE10A2
membrane-bound forms are degraded by the autophagy system, in
a similar fashion to most synaptic proteins (29, 55) and a previ-
ously suggested route for PDE10A (23). The decline in cAMP
degradation observed with the GAF-A mutants would enhance
PKA activity, which could phosphorylate the proteasome com-
ponent Rpt6, promote UPS function, and decrease PDE10A
levels even more (56). This faster turnover would explain the re-
duced levels of PDE10A detected in patients carrying the reces-
sive mutation Y107C (13). Furthermore, the complete lack of
PDE10A at the synapse could be responsible for the earlier clin-
ical manifestations observed in these patients compared to those
carrying the GAF-B mutations. Interestingly, patients with
biallelic mutations in the active site of the catalytic domain of
PDE10A (L675P) also showed an early manifestation of hy-
perkinetic movements (57).
A decrease in PDE10A expression has also been observed in
the striatum of individuals harboring the substitution F300L (17).
We have shown here that PDE10A protein carrying the domi-
nant mutations F300L and F334L generate aggregates in the
cytosol that reduce its availability at the plasma membrane.
Nonetheless, these substitutions do not affect the intrinsic PDE
activity of PDE10A at the inner surface of the cell, although a
lower level of the enzyme at the plasma membrane may disturb
cAMP signaling and would probably alter cyclic nucleotide dy-
namics in medium spiny neurons. The pathogenic effect of the
mutations in the GAF-B domain of PDE10A could further be
increased with the presence of aggregates resulting from im-
properly folded proteins. Aggregation can sometimes occur
when protein expression rates are too high, causing an overload
on the folding machinery (58). This phenomenon is one of the
limitations of the present study and possibly the reason why a
small proportion of HEK293 cells showed aggregates of the
PDE10A2 WT, which was not mirrored in striatal neurons.
Conversely, the high incidence of protein misfolding with the
F300L and F334L forms indicate that their abnormal association
is induced by these mutations. Both mutations affect highly
conserved aromatic residues located in the cAMP binding
pocket. The conformational view of this GAF-B region suggests
that these 2 phenylalanines are implicated in an edge-to-face
interaction and their substitution for a nonaromatic amino acid
could destabilize the domain and the folding of the protein.
Actually, aromatic pairs usually result in stabilizing such scaf-
folds (59) and a computational analysis found that aggregation-
prone sequences normally contained a pair of aromatic residues,
and at least one phenylalanine (60). These PDE10A2 F300L and
F334L aggregates cluster into specialized organelles called
aggresomes, which are large structures that sequester aggregated
proteins to minimize obstruction of cellular processes and deliver
them to lysosomes for degradation (37). Aggresome formation is
a dynamic process that can vary depending on the cell type (46,
61, 62), explaining the differences in size and components of the
PDE10A inclusions between the different cellular systems.
Particularly interesting is the sequestration of the autophagy-
adapter protein p62 into the PDE10A aggresomes in HEK293
cells as opposed to its absence in the neuronal aggregates.
Considering the smaller volume and dispersion of the PDE10A
in striatal inclusions, the lack of association with p62 could
correspond to an earlier accumulation stage or the implication of
a different receptor for lysosomal degradation, such as NBR1
(63). The function of the aggresomal structures is now assumed
to be a protective response against the toxic misfolded proteins
and the formation of these inclusions is dissociated from cell
death (64–66). Accordingly, the presence of the PDE10A F300L
or F334L aggregates did not reduce cellular viability and, indeed,
these cells experienced a slower stress-induced apoptosis, pos-
sibly due to an already impaired ALP that attenuates arsenite-
induced autophagic death. Aggresomes are a hallmark of many
neurodegenerative diseases where it is believed that the pro-
gressive accumulation of misfolded proteins leads to cellular
dysfunction, loss of synaptic connections, and selective brain
damage (67). Although data from overexpression models should
be approached with caution and patient-derived systems are
needed to corroborate misfolding and aggregation of these mu-
tants, it is plausible that a common pathological mechanism
occurs after expression of the aggregated-prone PDE10A forms.
Indeed, the PDE10A dominant mutations F300L and F334L,
unlike the mutations in the GAF-A domain, severely affect
striatal structure as shown by MRI scans (15).
PDE10A has been proposed as a novel therapeutic target for
diseases of the basal ganglia but inhibitors of this enzyme failed
to show efficacy in clinical trials for both HD and schizophrenia
(https://www.clinicaltrials.gov/: NCT02197130, NCT02074410,
NCT02342548, NCT01806896, NCT01939548, NCT01175135).
Our results show that an aberrant compartmentalization of
PDE10A underlies the hyperkinetic movement disorders ob-
served in individuals carrying mutations in this gene. Conse-
quently, the development of small molecules directed against
specific and highly localized PDE10A pools, such as agents tar-
geting the binding between the enzyme and zDHHCs or mem-
bers of the ALP or UPS, could be of interest from a therapeutic
perspective.
Materials and Methods
Culture and Transfection of HEK293 Cells and Primary Striatal Neurons. HEK293
cells were sourced from ATCC (CRL-1573) and primary striatal cultures were
collected from embryonic day 17 Sprague–Dawley rats (68). Cells were
transfected using Lipofectamine LTX with Plus reagent (ThermoFisher Sci-
entific) according to the manufacturer’s instructions. For further details, see
SI Appendix, Supplementary Methods.
Animals. All animal procedures were performed in compliance with Euro-
pean Union Directive 2010/63/EU and Animal (Scientific Procedures) Act 1986
with ethical review approval (University of Glasgow). Sprague–Dawley rats
were obtained from Charles River Laboratories and bred in our facilities.
Animals were housed in groups of 1 to 2 pregnant rats on a 12-h light/dark
cycle with food and water available ad libitum. All efforts were made to
minimize animal suffering and reduce the number of animals killed.
Immunoblot Analysis. Preparation of protein extracts, fractionation and im-
munoblot analysis is detailed in SI Appendix, Supplementary Methods.
Immunocytochemistry. Details regarding immunofluorescence can be found
in SI Appendix, Supplementary Methods.
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to a mock condition. (H and I) Quantification of phosphorylated VASP (in S157, H) or CREB (in S133, I) levels after forskolin treatment in the presence of the indicated
PDE10A variants relative to mock and normalized to GAPDH. Graphs depict mean ± SEM and significance was calculated by one-way ANOVA followed by Dunnett’s
post hoc test (**P = 0.0041; n = 3). (J and K) Cell survival analysis of transfected HEK293 cells with PDE10A2 F300L (J) or F334L (K) treated with 0.5 mM sodium arsenite
compared to a mock condition and cells expressing the WT form. Data were recorded using the real-time electrical impedance‐based xCELLigence system and rep-
resented as mean ± SEM. Statistical analysis was performed by two-way ANOVA followed by Tukey’s post hoc test (*P < 0.05, **P < 0.01; n = 5).
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Fig. 6. The aberrant localization of PDE10A GAF mutant proteins is replicated in striatal neurons. (A) Analysis of the different PDE10A-FLAG variants in
transfected rat primary striatal neurons (FLAG in green and DAPI in blue). (Scale bar, 10 μm.) (B) Analysis of PDE10A turnover after palmitoylation inhibition in
striatal neurons. Cells were treated with 100 μM 2-BP for 24 h and 20 μM MG132 for 5 h. (C) Quantification of PDE10A levels after palmitoylation and/or
proteasome inhibition in striatal neurons. Data normalized by neuron-specific enolase (NSE) levels is expressed as mean ± SEM relative to an untreated
condition and statistical analysis was performed by one-way ANOVA followed by Bonferroni’s post hoc test (**P = 0.0024, *P = 0.0245; n = 5). (D and G)
Colocalization analysis between the indicated PDE10A2 variants (green) and p62 (D) or ubiquitin (G) in rat striatal neurons. Arrows indicate the presence of
ubiquitin in PDE10A aggresomes and empty arrows show lack of recruitment of p62 to these neuronal aggregates. (E and H) Line intensity profiles corre-
sponding to the section shown in neurons expressing the PDE10A2 F300L form (dotted line). (F and I) PCC quantification of the indicated PDE10A2-FLAG
forms with p62 (F) or ubiquitin (I). Statistical significance was evaluated with one-way ANOVA followed by Dunnett’s post hoc test (*P = 0.0458; n = 9).
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Structural GAF-B Simulation. The mutations F300L and F334L, respectively,
were introduced to the known GAF-B structure of PDE10A (PDB ID code 2ZMF).
Both mutated structures were then minimized using the molecular operating
environment (MOE) without any restrictions (https://www.chemcomp.com/
Products.htm).
PDE Assay. PDE activity was measured using a radioactive cAMP hydrolysis
assay as described previously (69). Data dose–response curves and IC50 values
were calculated using GraphPad Prism. For further details, see SI Appendix,
Supplementary Methods.
Electrophysiology. Details on whole cell patch-clamp technique for analysis of
PDE10A modulation of CNG-mediated currents can be found in SI Appendix,
Supplementary Methods.
FRET Imaging. FRET imaging experiments were performed 24 to 48 h after
transfection of HEK293 cells as previously described (53), with the cyto-
solic EPAC-1 cAMP sensor (28) or a modified version encoding the FYXD1
subunit of Na2+/K+ ATPase in the N-terminal region to direct the probe to
the plasma membrane. For additional details, see SI Appendix, Supplementary
Methods.
Real-Time Cell Monitoring. Cell survival was monitored in real-time using the
electrical impedance‐based xCELLigence system (ACEA Biosciences), as de-
tailed in SI Appendix, Supplementary Methods.
Statistical Analysis. All data were expressed as mean ± SEM of at least 3
independent experiments. Statistical significance was determined by a one-
way ANOVA with Dunnett’s post hoc correction or two-way ANOVA fol-
lowed by a Tukey’s or Bonferroni’s post hoc test. A P value smaller than 0.05
was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Statistical analysis was performed using GraphPad Prism software.
Data and Materials Availability. All data used in the paper are present in the
main text and SI Appendix.
ACKNOWLEDGMENTS. We thank William Fuller and Jacqueline Howie for
technical help with palmitoylation assays. G.S.B. was supported by Medical
Research Council Grant MRCG0600765; and T.Z.D. and S.J.M. by Grant
NS101888. E.L.W. was funded by AstraZeneca, and received fellowships
from The Company of Biologists, Korner Travelling Fellowship Fund, and a
Biotechnology and Biological Sciences Research Council Flexible Talent
Mobility award for work that contributed to this manuscript. G.S.T. is a
fellow of the AstraZeneca postdoctoral program.
1. S. M. Nicola, The nucleus accumbens as part of a basal ganglia action selection circuit.
Psychopharmacology (Berl.) 191, 521–550 (2007).
2. I. Han, Y. You, J. H. Kordower, S. T. Brady, G. A. Morfini, Differential vulnerability of
neurons in Huntington’s disease: The role of cell type-specific features. J. Neurochem.
113, 1073–1091 (2010).
3. H. Hu, E. A. McCaw, A. L. Hebb, G. T. Gomez, E. M. Denovan-Wright, Mutant hun-
tingtin affects the rate of transcription of striatum-specific isoforms of phosphodi-
esterase 10A. Eur. J. Neurosci. 20, 3351–3363 (2004).
4. R. Ahmad et al., PET imaging shows loss of striatal PDE10A in patients with Hun-
tington disease. Neurology 82, 279–281 (2014).
5. H. Wilson et al., Loss of extra-striatal phosphodiesterase 10A expression in early
premanifest Huntington’s disease gene carriers. J. Neurol. Sci. 368, 243–248 (2016).
6. F. Niccolini et al., Loss of phosphodiesterase 10A expression is associated with pro-
gression and severity in Parkinson’s disease. Brain 138, 3003–3015 (2015).
7. F. Niccolini et al., Altered PDE10A expression detectable early before symptomatic
onset in Huntington’s disease. Brain 138, 3016–3029 (2015).
8. D. S. Russell et al., Change in PDE10 across early Huntington disease assessed by
[18F]MNI-659 and PET imaging. Neurology 86, 748–754 (2016).
9. A. L. Hebb, H. A. Robertson, E. M. Denovan-Wright, Striatal phosphodiesterase mRNA
and protein levels are reduced in Huntington’s disease transgenic mice prior to the
onset of motor symptoms. Neuroscience 123, 967–981 (2004).
10. M. Ooms et al., Early decrease of type 1 cannabinoid receptor binding and phos-
phodiesterase 10A activity in vivo in R6/2 Huntington mice. Neurobiol. Aging 35,
2858–2869 (2014).
11. H. Wood, Neurodegenerative disease: Changes in brain phosphodiesterase 10A levels
in neurodegenerative basal ganglia disorders. Nat. Rev. Neurol. 11, 483 (2015).
12. D. S. Russell et al., The phosphodiesterase 10 positron emission tomography tracer,
[18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol. 71,
1520–1528 (2014).
13. C. P. Diggle et al., Biallelic mutations in PDE10A lead to loss of striatal PDE10A and a
hyperkinetic movement disorder with onset in infancy. Am. J. Hum. Genet. 98, 735–
743 (2016).
14. S. Esposito et al., A PDE10A de novo mutation causes childhood-onset chorea with
diurnal fluctuations. Mov. Disord. 32, 1646–1647 (2017).
15. N. E. Mencacci et al., De novo mutations in PDE10A cause childhood-onset chorea
with bilateral striatal lesions. Am. J. Hum. Genet. 98, 763–771 (2016).
16. D. L. Narayanan, D. Deshpande, A. Das Bhowmik, D. R. Varma, A. Dalal, Familial
choreoathetosis due to novel heterozygous mutation in PDE10A. Am. J. Med. Genet.
A. 176, 146–150 (2018).
17. F. Niccolini et al., PDE10A and ADCY5 mutations linked to molecular and micro-
structural basal ganglia pathology. Mov. Disord. 33, 1961–1965 (2018).
18. C. Russwurm, D. Koesling, M. Russwurm, Phosphodiesterase 10A is tethered to a
synaptic signaling complex in striatum. J. Biol. Chem. 290, 11936–11947 (2015).
19. E. I. Charych, L. X. Jiang, F. Lo, K. Sullivan, N. J. Brandon, Interplay of palmitoylation
and phosphorylation in the trafficking and localization of phosphodiesterase 10A:
Implications for the treatment of schizophrenia. J. Neurosci. 30, 9027–9037 (2010).
20. K. Loughney et al., Isolation and characterization of PDE10A, a novel human 3′, 5′-
cyclic nucleotide phosphodiesterase. Gene 234, 109–117 (1999).
21. J. Kotera et al., Subcellular localization of cyclic nucleotide phosphodiesterase type
10A variants, and alteration of the localization by cAMP-dependent protein kinase-
dependent phosphorylation. J. Biol. Chem. 279, 4366–4375 (2004).
22. P. Vodicka et al., Effects of exogenous NUB1 expression in the striatum of HDQ175/Q7
mice. J. Huntingtons Dis. 5, 163–174 (2016).
23. P. Vodicka et al., Autophagy activation by transcription factor EB (TFEB) in striatum of
HDQ175/Q7 mice. J. Huntingtons Dis. 5, 249–260 (2016).
24. J. C. Price, S. Guan, A. Burlingame, S. B. Prusiner, S. Ghaemmaghami, Analysis of
proteome dynamics in the mouse brain. Proc. Natl. Acad. Sci. U.S.A. 107, 14508–14513
(2010).
25. T. C. Rich, T. E. Tse, J. G. Rohan, J. Schaack, J. W. Karpen, In vivo assessment of local
phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP
sensors. J. Gen. Physiol. 118, 63–78 (2001).
26. T. C. Rich et al., A uniform extracellular stimulus triggers distinct cAMP signals in
different compartments of a simple cell. Proc. Natl. Acad. Sci. U.S.A. 98, 13049–13054
(2001).
27. T. C. Rich et al., Cellular mechanisms underlying prostaglandin-induced transient
cAMP signals near the plasma membrane of HEK-293 cells. Am. J. Physiol. Cell Physiol.
292, C319–C331 (2007).
28. V. O. Nikolaev, M. Bünemann, L. Hein, A. Hannawacker, M. J. Lohse, Novel single
chain cAMP sensors for receptor-induced signal propagation. J. Biol. Chem. 279,
37215–37218 (2004).
29. E. J. Jin, F. R. Kiral, P. R. Hiesinger, The where, what, and when of membrane protein
degradation in neurons. Dev. Neurobiol. 78, 283–297 (2018).
30. Y. Li, B. R. Martin, B. F. Cravatt, S. L. Hofmann, DHHC5 protein palmitoylates flotillin-2
and is rapidly degraded on induction of neuronal differentiation in cultured cells. J.
Biol. Chem. 287, 523–530 (2012).
31. J. M. Hyttinen et al., Clearance of misfolded and aggregated proteins by aggrephagy
and implications for aggregation diseases. Ageing Res. Rev. 18, 16–28 (2014).
32. P. Grumati, I. Dikic, Ubiquitin signaling and autophagy. J. Biol. Chem. 293, 5404–5413
(2018).
33. G. Bjørkøy et al., p62/SQSTM1 forms protein aggregates degraded by autophagy and
has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171, 603–614
(2005).
34. L. L. Gomez, S. Alam, K. E. Smith, E. Horne, M. L. Dell’Acqua, Regulation of A-kinase
anchoring protein 79/150-cAMP-dependent protein kinase postsynaptic targeting by
NMDA receptor activation of calcineurin and remodeling of dendritic actin. J. Neu-
rosci. 22, 7027–7044 (2002).
35. M. Razi, E. Y. Chan, S. A. Tooze, Early endosomes and endosomal coatomer are re-
quired for autophagy. J. Cell Biol. 185, 305–321 (2009).
36. J. A. Olzmann, L. Li, L. S. Chin, Aggresome formation and neurodegenerative diseases:
Therapeutic implications. Curr. Med. Chem. 15, 47–60 (2008).
37. J. A. Johnston, C. L. Ward, R. R. Kopito, Aggresomes: A cellular response to misfolded
proteins. J. Cell Biol. 143, 1883–1898 (1998).
38. Y. Kawaguchi et al., The deacetylase HDAC6 regulates aggresome formation and cell
viability in response to misfolded protein stress. Cell 115, 727–738 (2003).
39. S. Waelter et al., Accumulation of mutant huntingtin fragments in aggresome-like
inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell 12,
1393–1407 (2001).
40. B. Wolozin, Regulated protein aggregation: Stress granules and neurodegeneration.
Mol. Neurodegener. 7, 56 (2012).
41. K. Lee et al., β-Catenin nuclear translocation in colorectal cancer cells is suppressed by
PDE10A inhibition, cGMP elevation, and activation of PKG. Oncotarget 7, 5353–5365
(2016).
42. D. J. Selkoe, Folding proteins in fatal ways. Nature 426, 900–904 (2003).
43. C. Swart et al., Neurodegenerative disorders: Dysregulation of a carefully maintained
balance? Exp. Gerontol. 58, 279–291 (2014).
44. J. Bai et al., Taurine protects against As2O3-induced autophagy in livers of rat off-
springs through PPARγ pathway. Sci. Rep. 6, 27733 (2016).
45. T. Qiu et al., Taurine attenuates arsenic-induced pyroptosis and nonalcoholic stea-
tohepatitis by inhibiting the autophagic-inflammasomal pathway. Cell Death Dis. 9,
946 (2018).
46. R. Garcia-Mata, Y. S. Gao, E. Sztul, Hassles with taking out the garbage: Aggravating
aggresomes. Traffic 3, 388–396 (2002).
47. J. P. Schülke, N. J. Brandon, Current understanding of PDE10A in the modulation of
basal ganglia circuitry. Adv. Neurobiol. 17, 15–43 (2017).
48. E. L. Whiteley, G. S. Tejeda, G. S. Baillie, N. J. Brandon, PDE10A mutations help to
unwrap the neurobiology of hyperkinetic disorders. Cell. Signal. 60, 31–38 (2019).
Tejeda et al. PNAS | January 7, 2020 | vol. 117 | no. 1 | 687
N
EU
RO
SC
IE
N
CE
D
ow
nl
oa
de
d 
at
 U
NI
V 
O
F 
G
LA
SG
O
W
 o
n 
Ja
nu
ar
y 
8,
 2
02
0 
49. N. Handa et al., Crystal structure of the GAF-B domain from human phosphodies-
terase 10A complexed with its ligand, cAMP. J. Biol. Chem. 283, 19657–19664 (2008).
50. S. L. Matte, T. M. Laue, R. H. Cote, Characterization of conformational changes and
protein-protein interactions of rod photoreceptor phosphodiesterase (PDE6). J. Biol.
Chem. 287, 20111–20121 (2012).
51. K. Lemonidis, M. C. Sanchez-Perez, L. H. Chamberlain, Identification of a novel se-
quence motif recognized by the ankyrin repeat domain of zDHHC17/13 S-acyl-
transferases. J. Biol. Chem. 290, 21939–21950 (2015).
52. G. S. Baillie, Compartmentalized signalling: Spatial regulation of cAMP by the action
of compartmentalized phosphodiesterases. FEBS J. 276, 1790–1799 (2009).
53. D. J. Henderson et al., The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated
in androgen-independent prostate cancer cells and mediates proliferation by com-
partmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. Br. J.
Cancer 110, 1278–1287 (2014).
54. S. Bhattacharyya, H. Yu, C. Mim, A. Matouschek, Regulated protein turnover: Snap-
shots of the proteasome in action. Nat. Rev. Mol. Cell Biol. 15, 122–133 (2014).
55. V. Hakim, L. D. Cohen, R. Zuchman, T. Ziv, N. E. Ziv, The effects of proteasomal in-
hibition on synaptic proteostasis. EMBO J. 35, 2238–2262 (2016).
56. J. T. Lin et al., Regulation of feedback between protein kinase A and the proteasome
system worsens Huntington’s disease. Mol. Cell. Biol. 33, 1073–1084 (2013).
57. C. Knopp et al., PDE10A mutation in two sisters with a hyperkinetic movement dis-
order—Response to levodopa. Parkinsonism Relat. Disord. 63, 240–242 (2019).
58. E. F. Halff, M. Versteeg, T. H. Brondijk, E. G. Huizinga, When less becomes more:
Optimization of protein expression in HEK293-EBNA1 cells using plasmid titration—A
case study for NLRs. Protein Expr. Purif. 99, 27–34 (2014).
59. K. Madhusudan Makwana, R. Mahalakshmi, Implications of aromatic-aromatic in-
teractions: From protein structures to peptide models. Protein Sci. 24 1920–1933
(2015).
60. P. W. Frederix et al., Exploring the sequence space for (tri-)peptide self-assembly to
design and discover new hydrogels. Nat. Chem. 7, 30–37 (2015).
61. R. García-Mata, Z. Bebök, E. J. Sorscher, E. S. Sztul, Characterization and dynamics of
aggresome formation by a cytosolic GFP-chimera. J. Cell Biol. 146, 1239–1254 (1999).
62. A. Tiwari et al., Caveolin-1 is an aggresome-inducing protein. Sci. Rep. 6, 38681 (2016).
63. V. Kirkin et al., A role for NBR1 in autophagosomal degradation of ubiquitinated
substrates. Mol. Cell 33, 505–516 (2009).
64. M. Arrasate, S. Mitra, E. S. Schweitzer, M. R. Segal, S. Finkbeiner, Inclusion body
formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature
431, 805–810 (2004).
65. F. Saudou, S. Finkbeiner, D. Devys, M. E. Greenberg, Huntingtin acts in the nucleus to
induce apoptosis but death does not correlate with the formation of intranuclear
inclusions. Cell 95, 55–66 (1998).
66. M. Tanaka et al., Aggresomes formed by alpha-synuclein and synphilin-1 are cyto-
protective. J. Biol. Chem. 279, 4625–4631 (2004).
67. C. A. Ross, M. A. Poirier, Protein aggregation and neurodegenerative disease. Nat.
Med. 10 (suppl.), S10–S17 (2004).
68. T. Falk, S. Zhang, E. L. Erbe, S. J. Sherman, Neurochemical and electrophysiological
characteristics of rat striatal neurons in primary culture. J. Comp. Neurol. 494, 275–289
(2006).
69. R. J. Marchmont, M. D. Houslay, A peripheral and an intrinsic enzyme constitute the
cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem. J. 187,
381–392 (1980).
688 | www.pnas.org/cgi/doi/10.1073/pnas.1916398117 Tejeda et al.
D
ow
nl
oa
de
d 
at
 U
NI
V 
O
F 
G
LA
SG
O
W
 o
n 
Ja
nu
ar
y 
8,
 2
02
0 
